Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination

PURPOSE: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, the toxicity of this pairing is unknown. We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhary, Mudit, Sen, Neilayan, Chowdhary, Akansha, Usha, Lydia, Cobleigh, Melody A., Wang, Dian, Patel, Kirtesh R., Barry, Parul N., Rao, Ruta D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639750/
https://www.ncbi.nlm.nih.gov/pubmed/31360799
http://dx.doi.org/10.1016/j.adro.2019.03.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639750/
https://www.ncbi.nlm.nih.gov/pubmed/31360799
http://dx.doi.org/10.1016/j.adro.2019.03.011

Ejemplares similares